TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Being Patient report explains four leading theories about what causes Alzheimer’s, a progressive disease that damages and kills neurons. Amyloid and tau have the strongest links to current research and treatments, but no single theory fully accounts for the disease, and its underlying causes remain under study.
Scientists have not established one cause of Alzheimer’s disease, and a Being Patient report describes four leading theories researchers use to explain how it develops. The theories focus on amyloid plaques, tau tangles, inflammation and other processes that may damage neurons, a question with consequences for diagnosis and the development of treatments.
Alzheimer’s is a progressive disease that damages and eventually kills neurons and disrupts their connections. Damage often begins in the hippocampus, which is central to forming new memories, and may later affect language, judgment, behavior and coordination. The report says researchers are still working out what sets this damage in motion.
The amyloid hypothesis proposes that beta-amyloid fragments build up outside neurons, forming plaques and potentially triggering further damage, including tau changes. The tau theory focuses on the protein tau inside neurons: tau normally supports structures that help cells function, while abnormal tau can form tangles associated with cell damage. These are prominent areas of research, but they do not by themselves settle the cause of Alzheimer’s.
The report also discusses inflammation and other biological processes as possible contributors. Researchers are investigating how these mechanisms may interact with amyloid and tau, rather than treating every theory as a complete, separate explanation. The material provided does not give detailed evidence or named researchers for all four theories, so the strength of each cannot be compared from this account alone.
How Theories Shape Alzheimer’s Research
Understanding what drives Alzheimer’s matters because the proposed causes guide both drug development and the search for reliable ways to identify disease. Treatments aimed at amyloid have already been tested and approved for some people in early stages, but their effects are limited and they do not cure the disease.
The report says the FDA-approved antibodies Leqembi (lecanemab) and Kisunla (donanemab) modestly slowed cognitive decline in clinical trials. They also carry risks, including brain swelling and bleeding, and require regular monitoring. Those results give researchers evidence that targeting amyloid can affect disease progression, but they do not prove that amyloid alone causes Alzheimer’s or explain why the disease starts.
Alzheimer's disease memory supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Plaques to Treatment Trials
In 1906, German psychiatrist Alois Alzheimer described plaques and twisted fibers in the brain of Auguste Deter, a patient who had experienced worsening memory loss and confusion. Those findings are now associated with amyloid plaques and tau tangles, the defining brain changes commonly linked to Alzheimer’s.
For more than three decades, the amyloid hypothesis has been a dominant influence on research and drug development. The report notes that Aduhelm (aducanumab), an earlier anti-amyloid drug, cleared plaques but had unconvincing evidence of clinical benefit; its maker discontinued it in 2024. Amyloid is also used in diagnosis: the report says it can be detected through PET scans and spinal-fluid testing, and that the FDA cleared a blood test to aid in identifying amyloid pathology in May 2025.
The report estimates that 7.4 million Americans aged 65 and older were living with Alzheimer’s dementia, citing the Alzheimer’s Association’s 2026 Facts and Figures report. That figure describes the U.S. population in that age group, not the number of people worldwide or all ages.
“Both γ-secretase and β-secretase inhibitors, which strongly inhibit amyloid-beta production, worsen cognitive and clinical performance in early and late stages of Alzheimer’s disease.”
— Bruno Imbimbo, a researcher at Chiesi Farmaceutici, speaking to Being Patient
anti-inflammatory brain health supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What Researchers Have Yet to Resolve
No single theory is established as a complete explanation for Alzheimer’s. The source describes a possible protective role for beta-amyloid and points to trials in which blocking its production worsened cognitive and clinical performance, but that statement is attributed to Imbimbo and is not a settled consensus presented by the report.
It also remains unclear how the proposed processes relate to one another, which mechanisms begin the disease, and why progression differs among individuals. The material provided does not detail the evidence behind every theory or identify a definitive cause. Plaque detection can inform diagnosis, but the report does not claim that a positive amyloid test alone explains an individual’s symptoms or future course.
As an affiliate, we earn on qualifying purchases.
Research Across Multiple Mechanisms
Researchers are continuing to test treatments aimed at amyloid and tau and to study whether inflammation and other processes contribute to neuronal damage. Further clinical trials and biological studies will be needed to determine which mechanisms are driving disease, whether they work together, and which patients might benefit from treatments targeting them.
For now, the developments described in the report do not amount to a newly confirmed cause or a cure. Anti-amyloid treatments remain options for some people in early stages, with potential benefits and risks requiring clinical monitoring. The report does not specify a next study result or announcement date.
As an affiliate, we earn on qualifying purchases.
Key Questions
What causes Alzheimer’s disease?
There is no single confirmed cause in the source report. Researchers are studying amyloid buildup, tau changes, inflammation and other biological processes that may contribute to neuronal damage.
Are amyloid plaques the cause of Alzheimer’s?
Amyloid plaques are a defining feature and a major focus of research, but their role is still debated. The report notes both treatments that target amyloid and concerns raised by some researchers about blocking amyloid production.
What is the difference between amyloid plaques and tau tangles?
Amyloid plaques form outside neurons from beta-amyloid fragments. Tau tangles involve abnormal tau inside neurons; tau normally helps support cell structures.
Do anti-amyloid drugs cure Alzheimer’s?
No. The report says Leqembi and Kisunla modestly slowed cognitive decline in clinical trials, but they are not cures and carry risks that require monitoring.
Can an amyloid test establish why someone has memory problems?
Amyloid PET scans, spinal-fluid tests and a blood test described in the report can help identify amyloid pathology. A test result does not establish a complete explanation for a person’s symptoms; diagnosis and medical decisions should be discussed with a qualified clinician.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
